Eyenovia Inc. has halted trading of its stock, $EYEN, as the company engages Chardan as an advisor to review strategic alternatives. This announcement comes amid speculation about the stock's potential for significant gains, with some traders suggesting a possible breakout and targets of $0.17 or higher. In related news, Lineage Cell Therapeutics has issued a letter to its stockholders, while Forward Air has announced a board review of strategic alternatives aimed at maximizing shareholder value.